ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK) inhibitors, such as crizotinib, alectinib, and lorlatinib [17, 18], as well as ROS1 (c-ros oncogene 1) inhibitors (i.e., crizotinib and entrectinib [19]) are effective against certain NSCLC patients.